Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bright Minds Biosciences Inc (DRUG)

Bright Minds Biosciences Inc (DRUG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 178,150
  • Shares Outstanding, K 4,434
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,470 K
  • EBIT $ -3 M
  • EBITDA $ -3 M
  • 60-Month Beta -7.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 37.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.06 +10.59%
on 12/19/24
49.46 -19.37%
on 12/02/24
+0.70 (+1.79%)
since 11/27/24
3-Month
0.94 +4,142.55%
on 10/09/24
79.02 -49.53%
on 10/18/24
+38.66 (+3,168.85%)
since 09/27/24
52-Week
0.93 +4,188.17%
on 04/30/24
79.02 -49.53%
on 10/18/24
+38.35 (+2,506.54%)
since 12/27/23

Most Recent Stories

More News
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

DRUG : 39.88 (-0.75%)
DRUG.CN : 57.4400 (+6.10%)
Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month

The reason for the stock's rapid ascent is a mystery.

DRUG : 39.88 (-0.75%)
NVDA : 137.01 (-2.09%)
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

DRUG : 39.88 (-0.75%)
DRUG.CN : 57.4400 (+6.10%)
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

DRUG : 39.88 (-0.75%)
DRUG.CN : 57.4400 (+6.10%)
MarketBeat Week in Review – 10/14 - 10/18

Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election.

WHR : 115.17 (-0.74%)
DRUG : 39.88 (-0.75%)
GOOGL : 192.76 (-1.45%)
NVDA : 137.01 (-2.09%)
CRWD : 354.99 (-2.76%)
CVX : 144.00 (+0.01%)
BAC : 44.34 (-0.47%)
OXY : 48.56 (+0.75%)
TSLA : 431.66 (-4.95%)
ABT : 114.99 (-0.24%)
XOM : 106.48 (-0.01%)
HOOD : 39.02 (-3.37%)
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

DRUG : 39.88 (-0.75%)
DRUG.CN : 57.4400 (+6.10%)
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

DRUG : 39.88 (-0.75%)
DRUG.CN : 57.4400 (+6.10%)
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNAâ„¢ Technology

DRUG : 39.88 (-0.75%)
AIFF : 2.62 (-2.96%)
DRUG.CN : 57.4400 (+6.10%)
Bright Minds Biosciences Stock Surges Almost 1,500%

Bright Minds Biosciences (NASDAQ: DRUG) soared 1,445% in a single day, trading over 100 million shares without any news.

DRUG : 39.88 (-0.75%)
Bright Minds is Unaware of Any Material Changes

Vancouver, British Columbia--(Newsfile Corp. - October 15, 2024) - At the request of CIRO, Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") wishes to confirm that...

DRUG : 39.88 (-0.75%)
DRUG.CN : 57.4400 (+6.10%)

Business Summary

Bright Minds Biosciences is a biotechnology company. It focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain. Bright Minds Biosciences is based in VANCOUVER, British Columbia.

See More

Key Turning Points

3rd Resistance Point 44.48
2nd Resistance Point 42.69
1st Resistance Point 41.28
Last Price 39.88
1st Support Level 38.08
2nd Support Level 36.29
3rd Support Level 34.88

See More

52-Week High 79.02
Fibonacci 61.8% 49.19
Fibonacci 50% 39.97
Last Price 39.88
Fibonacci 38.2% 30.76
52-Week Low 0.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar